Hematology Medical Director, VEXAS
Listed on 2026-09-12
-
Healthcare
Healthcare Consultant, Medical Education
Company Description
At Sobi, we believe diversity drives innovation and inclusion creates stronger teams. We are committed to building a workplace where everyone feels valued and empowered to contribute.
At Sobi, each person brings their unique talents to work as a team and make a difference. We are dedicated to developing and delivering innovative therapies to improve the lives of people who live with a rare disease. Our edge comes from our team of people and our commitment to patients.
Our Mission And Culture At Sobi North America Get Us Excited To Come To Work Every Day, But Here Are a Few More Reasons To Join Our Team
- Competitive compensation for your work
- Generous time off policy
- Opportunity to broaden your horizons by attending popular conferences
- Emphasis on work/life balance
- Collaborative and team-oriented environment
- Making a positive impact to help ultra-rare disease patients who are in need of life saving treatments
The Hematology Medical Director, VEXAS leads medical strategy and external engagement for the VEXAS disease area within the Vonjo (pacritinib) Medical Affairs organization. This is an exciting opportunity for an experienced medical leader to shape how Sobi supports the VEXAS patient and provider community—building scientific credibility and trust across the hematology, rheumatology, dermatology, and inflammation communities in an emerging and complex disease area.
Reporting to the Head of Vonjo Medical Affairs, this individual will serve as the lead medical voice for VEXAS, driving the US medical strategy and partnering closely with Field Medical to engage and educate healthcare providers (HCPs), medical organizations, payers, and patient advocacy groups. The role also serves as the medical lead on the Brand Team and collaborates cross-functionally to advance shared business goals.
MajorResponsibilities
- Serve as the lead medical strategist for VEXAS, providing strategic direction for medical strategy, brand-aligned tactics, and external clinician engagement across academic, community, and multidisciplinary care settings
- Partner with the Field Medical Team to develop and strengthen KOL and key institution engagement plans, positioning Sobi as the scientific partner of choice for VEXAS
- Collaborate with Field Medical to identify resource needs and co-develop field materials and tactics specific to VEXAS
- Lead planning and execution of advisory boards and educational activities, including webinars, medical round tables, symposia, and congress presence
- Generate and share medical insights with internal partners, using them to refine strategy and tactics
- Build strong collaborative relationships across Market Access, Medical Information, Clinical Development, Sales, and Marketing
- Contribute to evidence generation projects, real-world evidence studies, and publications supporting the VEXAS disease area
- Support launch readiness through disease education, articulation of unmet need, and evidence generation planning
- Uphold the collaborative culture of Hematology Medical Affairs—one that respects and appreciates every team member while encouraging one another toward excellence and a shared purpose
- MD, PhD, or PharmD
- Minimum of 3 years of experience as an Associate or Medical Director
- Ability to travel up to 50%, primarily domestic
- Excellent communication and presentation skills, including the ability to translate complex scientific concepts for varied audiences
- Demonstrated ability to build meaningful, bi-directional relationships with the medical community
- Strong scientific and clinical acumen paired with strategic and analytical thinking
- Proven leadership across core Medical Affairs functions, such as evidence generation, publications, medical education, and strategy…
(If this job is in fact in your jurisdiction, then you may be using a Proxy or VPN to access this site, and to progress further, you should change your connectivity to another mobile device or PC).